Financial press releases

2023 full-year business and earnings

Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma

Phase 2 clinical trial for the treatment of Alzheimer’s disease

Completion of the 1st phase of double-blind treatment, with good patient retention and acceptance of the treatment – January, 29 2024

2023 first-half business and earnings – October, 27 2023

Participation in the 16th International Clinical Trials on Alzheimer’s Disease (CTAD), in Boston from 24 to 27 October 2023, and presentation of a poster on its current research. – October, 23 2023

End of enrollement of the 68 patients in Medesis Pharma phase 2 clinical study of Nanolithium for the treatment of Alzheimer’s disease – October, 17 2023

Publication of a scientific article in the journal of alzheimer’s disease on the use of lithium for the treatment of alzheimer’s disease – October, 11 2023

MEDESIS PHARMA receives approval from the Montpellier commercial court to open a safeguard procedure – October 3 2023

Medesis pharma recognized as a 2023 prix Galien USA nominee for Best Startup – August 2, 2023

Medesis pharma presents a scientific poster at the international conference of the alzheimer association in Amsterdam – July 13, 2023

Notice of allowance in the United States of the patent protecting the radiation protection treatment against irradiation during a nuclear accident  – July 4, 2023

Outcome of the montpellier commercial court ruling in the legal dispute between medesis pharma and bpi france – June 8, 2023

Favorable report from IDSMB experts on the ongoing phase 2 clinical study on Nanolithium in the treatment of Alzheimer’s disease – May 23, 2023

2022 full-year business and earnings – April 17, 2023

Medesis Pharma signs a partnership with Partner International, world leader in transactions between biotechs and pharmaceutical laboratories – April 4, 2023

Medesis pharma sets up bond financing for a potential maximum nominal amount of 2,500,000 euros – March 31, 2023

Medesis Pharma presents a scientific poster at the european RNA leaders congress in Basel – March 13, 2023

New patent filed protecting the technical optimization of the Aonys microemulsion and its efficacy applied for all water-soluble pharmaceutical active ingredients – March 7, 2023

Patent registered in Eurasia to protect the Cesium decorporation drug candidate – Dec. 12, 2022

Medesis Pharma presents a scientific poster at the clinical trials on alzheimer’s disease conference in San Francisco – Nov. 28, 2022

Medesis Pharma announces the constitution of a permanent scientific advisory board of experts in neurodenegerative diseases – Nov. 21, 2022

Medesis Pharma further strengthens its governance – Oct. 4, 2022

Medesis receives a grant from AFM-TELETHON to finance the first phases of the development of NanosiRNA-HD RNA interference therapy for Huntington’s disease – July 20, 2022

Treatment of Alzheimer’s disease with Nanolithium first inclusion of patients in the phase II clinical study – June 13, 2022

Development of NanoManganese for the optimization of radiotherapy in cancer treatment – April 20, 2022

2021 full-year business and earnings   – April 13, 2022

Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy – April 5, 2022

U.S. patent protection registration of the future drug allowing the decorporation of cesium – March 24, 2022

Medesis Pharma confirms its eligibility for the PEA-PME – January 14, 2022 (in french only)

Medesis Pharma presents a scientific poster at the Congress on Gene Therapy for the Treatment of Neurological Diseases – December 2, 2021
Treatment of severe forms of Covid-19: Medesis Pharma phase II clinical study authorized by Brazilian health authorities – November 22, 2021
Treatment of Alzheimer disease : Medesis Pharma phase II clinical study authorized by ANSM (Agence nationale de sécurité du médicament et des produits de santé; France) – September 21, 2021

Half-year activities and results – September 16, 2021 (in french only)

Medesis Pharma files a European patent with TRANSGENE, the result of their joint work – September 1, 2021

Repositioning of the NanoManganese program outside the EU after an ANSM refusal – August 26, 2021 (in french only)

Report of the Combined General Meeting – June 15, 2021 (in french only)

Drug candidate development plan for treatment of Huntington disease receives favorable opinion from the EMA – June 3, 2021 (in french only)

Initiation of analyst coverage by Invest Securities – May 7, 2021 (in french only)

Availability of the 2020 Annual Financial Report – April 28, 2021 (in french only)

Annual results and outlook for 2021 (in french only)

Description of the share buyback program and implementation of a liquidity contract – March 12, 2021 (in french only)

Medesis Pharma raises € 7.35m following the very successful IPO on Euronext Paris – February 10, 2021 (in french only)

Medesis Pharma launches its IPO on Euronext Growth Paris – January 26, 2021 (in french only)